Exploring the effect of dapagliflozin on coronary inflammation in type 2 diabetes patients based on the coronary artery perivascular fat attenuation index
Dapagliflozin treatment is associated with a significant reduction in coronary artery inflammation in T2DM patients, which may partly explain its beneficial effects on reducing cardiovascular risk.
Authors
- Luping Ren (ORCID: https://orcid.org/0000-0003-3662-8847)
- Dan Liu (ORCID: https://orcid.org/0000-0002-1852-5396)
- Tian Zhang (ORCID: https://orcid.org/0000-0001-9007-7965)
- Jingyi Zhang (ORCID: https://orcid.org/0000-0001-5801-5764)
- Qing Hu (ORCID: https://orcid.org/0000-0001-8067-6569)
- Rongguo Fu (ORCID: https://orcid.org/0009-0005-9677-1401)
- Guangyao Song
- Xuehua Liu
Institutions
- Hebei Medical University (CN)
- Hebei North University (CN)
- Hebei General Hospital (CN)
Publication Details
- Journal
- Cardiovascular Diabetology
- Published
- 2025-04-18
- DOI
- https://doi.org/10.1186/s12933-025-02723-7
- Citations
- 3
- Primary Topic
- Cardiovascular Disease and Adiposity
- Type
- article
- Field-Weighted Citation Impact
- 4.16
Funders
- National Natural Science Foundation of China
- Natural Science Foundation of Hebei Province